Literature DB >> 18617371

Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia.

Faith Dickerson1, Elizabeth Rubalcaba, Raphael Viscidi, Shuojia Yang, Cassie Stallings, Anne Sullens, Andrea Origoni, Flora Leister, Robert Yolken.   

Abstract

Type 2 diabetes is a major health problem in individuals with schizophrenia. The genetic basis of diabetes risk in individuals with schizophrenia has not been previously defined. We measured polymorphisms in a human endogenous retrovirus, Herv K-18, which is located in the CD48 signaling lymphocyte activating (SLAM) gene on chromosome 1. The study population consisted of 229 individuals with schizophrenia, 29 of whom had a history of type 2 diabetes, as well as 136 control individuals without a history of a psychiatric disorder or type 2 diabetes. We found that a haplotype defined by 2 polymorphisms in the envelope region of Herv K-18 is highly associated with type 2 diabetes in a population of 229 individuals with schizophrenia, with an odds ratio of 9.0 (95% confidence limits 2.3-34.7, p<.001) adjusted for race, gender and type of antipsychotic medication. Lower levels of association were found in other polymorphisms located in the 3'untranslated region of Herv K-18 and in adjacent loci in CD48. Polymorphisms in endogenous retroviruses which are located near immunomodulatory genes may constitute risk factors for diabetes in individuals with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18617371     DOI: 10.1016/j.schres.2008.05.005

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  Metabolic effects of olanzapine in patients with newly diagnosed psychosis.

Authors:  Emilio Fernandez-Egea; Brian Miller; Clemente Garcia-Rizo; Miguel Bernardo; Brian Kirkpatrick
Journal:  J Clin Psychopharmacol       Date:  2011-04       Impact factor: 3.153

Review 2.  Human endogenous retrovirus-K (HML-2): a comprehensive review.

Authors:  Marta Garcia-Montojo; Tara Doucet-O'Hare; Lisa Henderson; Avindra Nath
Journal:  Crit Rev Microbiol       Date:  2018-10-14       Impact factor: 7.624

Review 3.  Endogenous retrovirus-K and nervous system diseases.

Authors:  Mamneet Manghera; Jennifer Ferguson; Renée Douville
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

4.  Molecular characterization of a novel gammaretrovirus in killer whales (Orcinus orca).

Authors:  Sarah A Lamere; Judy A St Leger; Mark D Schrenzel; Simon J Anthony; Bruce A Rideout; Daniel R Salomon
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

Review 5.  Human endogenous retroviruses and the nervous system.

Authors:  Renée N Douville; Avindra Nath
Journal:  Handb Clin Neurol       Date:  2014

Review 6.  Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus.

Authors:  Yutaka Mizuki; Shinji Sakamoto; Yuko Okahisa; Yuji Yada; Nozomu Hashimoto; Manabu Takaki; Norihito Yamada
Journal:  Int J Neuropsychopharmacol       Date:  2021-05-18       Impact factor: 5.176

7.  Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses.

Authors:  Ravi P Subramanian; Julia H Wildschutte; Crystal Russo; John M Coffin
Journal:  Retrovirology       Date:  2011-11-08       Impact factor: 4.602

Review 8.  Human Endogenous Retroviruses as Pathogenic Factors in the Development of Schizophrenia.

Authors:  Gorjan Slokar; Gregor Hasler
Journal:  Front Psychiatry       Date:  2016-01-11       Impact factor: 4.157

Review 9.  Inside the Envelope: Endogenous Retrovirus-K Env as a Biomarker and Therapeutic Target.

Authors:  Marie-Josée Nadeau; Mamneet Manghera; Renée N Douville
Journal:  Front Microbiol       Date:  2015-11-13       Impact factor: 5.640

10.  Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver.

Authors:  Laura B Ferguson; Lingling Zhang; Shi Wang; Courtney Bridges; R Adron Harris; Igor Ponomarev
Journal:  Front Mol Neurosci       Date:  2018-09-19       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.